Product Name: Cinnarizine

Chemical Properties

Product Name: Cinnarizine
Cas No.: 298-57-7
M.Wt: 368.51
Formula: C26H28N2

Chemical Name: 1-benzhydryl-4-cinnamylpiperazine
Canonical SMILES: C1(/C=C/CN2CCN(C(C3=CC=CC=C3)C4=CC=CC=C4)CC2)=CC=CC=C1
Solubility: Soluble in DMSO
Storage: Store at -20°C

General tips: For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shopping Condition: Evaluation sample solution: ship with blue ice
All other available size: ship with RT, or blue ice upon request

Biological Activity

Targets: Neuroscience
Pathways: Histamine Receptor

Description:

Cinnarizine is a calcium channel blocker. Blockers of calcium channel are drugs disrupting the calcium movement via calcium channels, which are usually used as antihypertensive therapies to decrease blood pressure in hypertension patients.

In vitro: Previous study found that cinnarizine could inhibit the phosphorylation of both arterial myosin P-light chain and arterial actomyosin superprecipitation. Moreover, the concomitant
inhibition of arterial superprecipitation and phosphorylation by perhexiline and cinnarizine was found to be similar to that of W-7. Such inhibitory effect was then characterized by a rightward shift in the pCa superprecipitation, depressed maximum activity as well as attenuation by exogenous calmodulin [1].

In vivo: Previous animal study showed that augmented effects were obtained in MES seizure model when cinnarizine was combined with sodium valproate. Whereas, in PTZ-induced seizures, augmented effects were obtained when nifedipine was combined with sodium valproate [2].

Clinical trial: The anti-vertigo effect of cinnarizine was evaluated in a double blinded, controlled study on forty patients with well characterized peripheral or central vestibular disorders. Electronystagmography results did not show obviously detectable differences between patients treated with cinnarizine and placebo, and only a temporary depressant effect on vestibular nystagmus was observed in five healthy volunteers when cinnarizine dose was increased to 150 mg. In addition, cinnarizine was found to be generally well tolerated [3].

Reference:

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most ApexBio products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

ApexBio Technology

www.apexbt.com